Stocks of Rockwell Medical Inc. (NASDAQ:RMTI) traded higher last session on Wall Street, down -4.12% to $5.58.
According to the data, Rockwell Medical Inc. (NASDAQ:RMTI) has 2 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.00 and a low of $6.00, we find $7.50. Given the previous closing price of $5.82, this indicates a potential upside of 28.87 percent. RMTI stock price is now 60.44% away from the 50-day moving average and 185.47% away from the 200-day moving average. The market capitalization of the company currently stands at $75.78M.
A total of 0 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $7.50 as their price target over the next twelve months.
With the price target of $10, Piper Jaffray recently initiated with Overweight rating for Rockwell Medical Inc. (NASDAQ: RMTI).
A total of 5.58% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RMTI stock. A new stake in Rockwell Medical Inc. shares was purchased by RAYMOND JAMES & ASSOCIATES during the first quarter worth $334,000. SIGMA PLANNING CORP invested $141,000 in shares of RMTI during the first quarter. In the first quarter, NUVEEN ASSET MANAGEMENT, LLC acquired a new stake in Rockwell Medical Inc. valued at approximately $101,000. WIPFLI FINANCIAL ADVISORS LLC, acquired a new stake in RMTI for approximately $11,000. In total, there are 39 active investors with 22.30% ownership of the company’s stock.
During the past 12 months, Rockwell Medical Inc. has had a low of $0.84 and a high of $6.19. As of last week, the company has a debt-to-equity ratio of 0.74, a current ratio of 2.00, and a quick ratio of 1.60. The fifty day moving average price for RMTI is $3.55 and a two-hundred day moving average price translates $1.98 for the stock.
The latest earnings results from Rockwell Medical Inc. (NASDAQ: RMTI) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.1, beating analysts’ expectations of -$0.16 by 0.06. This compares to -$0.84 EPS in the same period last year. The net profit margin was -17.40% and return on equity was -84.30% for RMTI. The company reported revenue of $19.67 million for the quarter, compared to $16.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 21.98 percent. For the current quarter, analysts expect RMTI to generate $19.98M in revenue.
Rockwell Medical Inc.(RMTI) Company Profile
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in patients undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including cleaning agents, 6% bleach for disinfection, citric acid descale, filtration salts, and other supplies used by hemodialysis providers. The company’s dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
